TREM2 in neurodegeneration: Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease

Sruti Rayaprolu, Bianca Mullen, Matt Baker, Timothy Lynch, Elizabeth Finger, William W. Seeley, Kimmo J. Hatanpaa, Catherine Lomen-Hoerth, Andrew Kertesz, Eileen H. Bigio, Carol Lippa, Keith Anthony Josephs, David S Knopman, Charles L. White, Richard John Caselli, Ian R. Mackenzie, Bruce L. Miller, Magdalena Boczarska-Jedynak, Grzegorz Opala, Anna Krygowska-WajsMaria Barcikowska, Steven G Younkin, Ronald Carl Petersen, Nilufer Taner, Ryan J. Uitti, James F Meschia, Kevin B. Boylan, Bradley F Boeve, Neill R Graff Radford, Zbigniew K Wszolek, Dennis W Dickson, Rosa V Rademakers, Owen A Ross

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

Background: A rare variant in the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) gene has been reported to be a genetic risk factor for Alzheimer's disease by two independent groups (Odds ratio between 2.9-4.5). Given the key role of TREM2 in the effective phagocytosis of apoptotic neuronal cells by microglia, we hypothesized that dysfunction of TREM2 may play a more generalized role in neurodegeneration. With this in mind we set out to assess the genetic association of the Alzheimer's disease-related risk variant in TREM2 (rs75932628, p.R47H) with other related neurodegenerative disorders. Results: The study included 609 patients with frontotemporal dementia, 765 with amyotrophic lateral sclerosis, 1493 with Parkinson's disease, 772 with progressive supranuclear palsy, 448 with ischemic stroke and 1957 controls subjects free of neurodegenerative disease. A significant association was observed for the TREM2 p.R47H substitution in susceptibility to frontotemporal dementia (OR = 5.06; p-value = 0.001) and Parkinson's disease (OR = 2.67; p-value = 0.026), while no evidence of association with risk of amyotrophic lateral sclerosis, progressive supranuclear palsy or ischemic stroke was observed. Conclusions: Our results suggest that the TREM2 p.R47H substitution is a risk factor for frontotemporal dementia and Parkinson's disease in addition to Alzheimer's disease. These findings suggest a more general role for TREM2 dysfunction in neurodegeneration, which could be related to its role in the immune response.

Original languageEnglish (US)
Article number19
JournalMolecular Neurodegeneration
Volume8
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Frontotemporal Dementia
Myeloid Cells
Parkinson Disease
Progressive Supranuclear Palsy
Alzheimer Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Stroke
Microglia
Phagocytosis
Odds Ratio
Genes

Keywords

  • Frontotemporal dementia
  • Genetic association
  • Parkinson disease
  • TREM2

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Clinical Neurology
  • Molecular Biology

Cite this

TREM2 in neurodegeneration : Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. / Rayaprolu, Sruti; Mullen, Bianca; Baker, Matt; Lynch, Timothy; Finger, Elizabeth; Seeley, William W.; Hatanpaa, Kimmo J.; Lomen-Hoerth, Catherine; Kertesz, Andrew; Bigio, Eileen H.; Lippa, Carol; Josephs, Keith Anthony; Knopman, David S; White, Charles L.; Caselli, Richard John; Mackenzie, Ian R.; Miller, Bruce L.; Boczarska-Jedynak, Magdalena; Opala, Grzegorz; Krygowska-Wajs, Anna; Barcikowska, Maria; Younkin, Steven G; Petersen, Ronald Carl; Taner, Nilufer; Uitti, Ryan J.; Meschia, James F; Boylan, Kevin B.; Boeve, Bradley F; Graff Radford, Neill R; Wszolek, Zbigniew K; Dickson, Dennis W; Rademakers, Rosa V; Ross, Owen A.

In: Molecular Neurodegeneration, Vol. 8, No. 1, 19, 2013.

Research output: Contribution to journalArticle

Rayaprolu, S, Mullen, B, Baker, M, Lynch, T, Finger, E, Seeley, WW, Hatanpaa, KJ, Lomen-Hoerth, C, Kertesz, A, Bigio, EH, Lippa, C, Josephs, KA, Knopman, DS, White, CL, Caselli, RJ, Mackenzie, IR, Miller, BL, Boczarska-Jedynak, M, Opala, G, Krygowska-Wajs, A, Barcikowska, M, Younkin, SG, Petersen, RC, Taner, N, Uitti, RJ, Meschia, JF, Boylan, KB, Boeve, BF, Graff Radford, NR, Wszolek, ZK, Dickson, DW, Rademakers, RV & Ross, OA 2013, 'TREM2 in neurodegeneration: Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease', Molecular Neurodegeneration, vol. 8, no. 1, 19. https://doi.org/10.1186/1750-1326-8-19
Rayaprolu, Sruti ; Mullen, Bianca ; Baker, Matt ; Lynch, Timothy ; Finger, Elizabeth ; Seeley, William W. ; Hatanpaa, Kimmo J. ; Lomen-Hoerth, Catherine ; Kertesz, Andrew ; Bigio, Eileen H. ; Lippa, Carol ; Josephs, Keith Anthony ; Knopman, David S ; White, Charles L. ; Caselli, Richard John ; Mackenzie, Ian R. ; Miller, Bruce L. ; Boczarska-Jedynak, Magdalena ; Opala, Grzegorz ; Krygowska-Wajs, Anna ; Barcikowska, Maria ; Younkin, Steven G ; Petersen, Ronald Carl ; Taner, Nilufer ; Uitti, Ryan J. ; Meschia, James F ; Boylan, Kevin B. ; Boeve, Bradley F ; Graff Radford, Neill R ; Wszolek, Zbigniew K ; Dickson, Dennis W ; Rademakers, Rosa V ; Ross, Owen A. / TREM2 in neurodegeneration : Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. In: Molecular Neurodegeneration. 2013 ; Vol. 8, No. 1.
@article{37f073f897384a19b0b146e18159ab50,
title = "TREM2 in neurodegeneration: Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease",
abstract = "Background: A rare variant in the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) gene has been reported to be a genetic risk factor for Alzheimer's disease by two independent groups (Odds ratio between 2.9-4.5). Given the key role of TREM2 in the effective phagocytosis of apoptotic neuronal cells by microglia, we hypothesized that dysfunction of TREM2 may play a more generalized role in neurodegeneration. With this in mind we set out to assess the genetic association of the Alzheimer's disease-related risk variant in TREM2 (rs75932628, p.R47H) with other related neurodegenerative disorders. Results: The study included 609 patients with frontotemporal dementia, 765 with amyotrophic lateral sclerosis, 1493 with Parkinson's disease, 772 with progressive supranuclear palsy, 448 with ischemic stroke and 1957 controls subjects free of neurodegenerative disease. A significant association was observed for the TREM2 p.R47H substitution in susceptibility to frontotemporal dementia (OR = 5.06; p-value = 0.001) and Parkinson's disease (OR = 2.67; p-value = 0.026), while no evidence of association with risk of amyotrophic lateral sclerosis, progressive supranuclear palsy or ischemic stroke was observed. Conclusions: Our results suggest that the TREM2 p.R47H substitution is a risk factor for frontotemporal dementia and Parkinson's disease in addition to Alzheimer's disease. These findings suggest a more general role for TREM2 dysfunction in neurodegeneration, which could be related to its role in the immune response.",
keywords = "Frontotemporal dementia, Genetic association, Parkinson disease, TREM2",
author = "Sruti Rayaprolu and Bianca Mullen and Matt Baker and Timothy Lynch and Elizabeth Finger and Seeley, {William W.} and Hatanpaa, {Kimmo J.} and Catherine Lomen-Hoerth and Andrew Kertesz and Bigio, {Eileen H.} and Carol Lippa and Josephs, {Keith Anthony} and Knopman, {David S} and White, {Charles L.} and Caselli, {Richard John} and Mackenzie, {Ian R.} and Miller, {Bruce L.} and Magdalena Boczarska-Jedynak and Grzegorz Opala and Anna Krygowska-Wajs and Maria Barcikowska and Younkin, {Steven G} and Petersen, {Ronald Carl} and Nilufer Taner and Uitti, {Ryan J.} and Meschia, {James F} and Boylan, {Kevin B.} and Boeve, {Bradley F} and {Graff Radford}, {Neill R} and Wszolek, {Zbigniew K} and Dickson, {Dennis W} and Rademakers, {Rosa V} and Ross, {Owen A}",
year = "2013",
doi = "10.1186/1750-1326-8-19",
language = "English (US)",
volume = "8",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - TREM2 in neurodegeneration

T2 - Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease

AU - Rayaprolu, Sruti

AU - Mullen, Bianca

AU - Baker, Matt

AU - Lynch, Timothy

AU - Finger, Elizabeth

AU - Seeley, William W.

AU - Hatanpaa, Kimmo J.

AU - Lomen-Hoerth, Catherine

AU - Kertesz, Andrew

AU - Bigio, Eileen H.

AU - Lippa, Carol

AU - Josephs, Keith Anthony

AU - Knopman, David S

AU - White, Charles L.

AU - Caselli, Richard John

AU - Mackenzie, Ian R.

AU - Miller, Bruce L.

AU - Boczarska-Jedynak, Magdalena

AU - Opala, Grzegorz

AU - Krygowska-Wajs, Anna

AU - Barcikowska, Maria

AU - Younkin, Steven G

AU - Petersen, Ronald Carl

AU - Taner, Nilufer

AU - Uitti, Ryan J.

AU - Meschia, James F

AU - Boylan, Kevin B.

AU - Boeve, Bradley F

AU - Graff Radford, Neill R

AU - Wszolek, Zbigniew K

AU - Dickson, Dennis W

AU - Rademakers, Rosa V

AU - Ross, Owen A

PY - 2013

Y1 - 2013

N2 - Background: A rare variant in the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) gene has been reported to be a genetic risk factor for Alzheimer's disease by two independent groups (Odds ratio between 2.9-4.5). Given the key role of TREM2 in the effective phagocytosis of apoptotic neuronal cells by microglia, we hypothesized that dysfunction of TREM2 may play a more generalized role in neurodegeneration. With this in mind we set out to assess the genetic association of the Alzheimer's disease-related risk variant in TREM2 (rs75932628, p.R47H) with other related neurodegenerative disorders. Results: The study included 609 patients with frontotemporal dementia, 765 with amyotrophic lateral sclerosis, 1493 with Parkinson's disease, 772 with progressive supranuclear palsy, 448 with ischemic stroke and 1957 controls subjects free of neurodegenerative disease. A significant association was observed for the TREM2 p.R47H substitution in susceptibility to frontotemporal dementia (OR = 5.06; p-value = 0.001) and Parkinson's disease (OR = 2.67; p-value = 0.026), while no evidence of association with risk of amyotrophic lateral sclerosis, progressive supranuclear palsy or ischemic stroke was observed. Conclusions: Our results suggest that the TREM2 p.R47H substitution is a risk factor for frontotemporal dementia and Parkinson's disease in addition to Alzheimer's disease. These findings suggest a more general role for TREM2 dysfunction in neurodegeneration, which could be related to its role in the immune response.

AB - Background: A rare variant in the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) gene has been reported to be a genetic risk factor for Alzheimer's disease by two independent groups (Odds ratio between 2.9-4.5). Given the key role of TREM2 in the effective phagocytosis of apoptotic neuronal cells by microglia, we hypothesized that dysfunction of TREM2 may play a more generalized role in neurodegeneration. With this in mind we set out to assess the genetic association of the Alzheimer's disease-related risk variant in TREM2 (rs75932628, p.R47H) with other related neurodegenerative disorders. Results: The study included 609 patients with frontotemporal dementia, 765 with amyotrophic lateral sclerosis, 1493 with Parkinson's disease, 772 with progressive supranuclear palsy, 448 with ischemic stroke and 1957 controls subjects free of neurodegenerative disease. A significant association was observed for the TREM2 p.R47H substitution in susceptibility to frontotemporal dementia (OR = 5.06; p-value = 0.001) and Parkinson's disease (OR = 2.67; p-value = 0.026), while no evidence of association with risk of amyotrophic lateral sclerosis, progressive supranuclear palsy or ischemic stroke was observed. Conclusions: Our results suggest that the TREM2 p.R47H substitution is a risk factor for frontotemporal dementia and Parkinson's disease in addition to Alzheimer's disease. These findings suggest a more general role for TREM2 dysfunction in neurodegeneration, which could be related to its role in the immune response.

KW - Frontotemporal dementia

KW - Genetic association

KW - Parkinson disease

KW - TREM2

UR - http://www.scopus.com/inward/record.url?scp=84879113935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879113935&partnerID=8YFLogxK

U2 - 10.1186/1750-1326-8-19

DO - 10.1186/1750-1326-8-19

M3 - Article

C2 - 23800361

AN - SCOPUS:84879113935

VL - 8

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 19

ER -